#United States #Jupiter #Myosin Therapeutics #Cancer Innovation #STAR-GBM

Myosin Therapeutics Secures $2 Million Grant for STAR-GBM Clinical Trial

Myosin Therapeutics, a biotechnology firm based in Jupiter, Florida, has recently been awarded a substantial $2 million grant from the Florida Department of Health. This funding comes through the Casey DeSantis Florida Cancer Innovation Fund (FCIF) and is aimed at bolstering the company's Phase 1/2 clinical trial for MT-125, a promising therapeutic candidate aimed at treating glioblastoma (GBM) in newly diagnosed patients.

The Florida Cancer Innovation Fund is a statewide initiative designed to accelerate the development of groundbreaking cancer therapies while nurturing the life sciences ecosystem within Florida. Myosin Therapeutics was selected for this funding due to the scientific innovation and clinical potential linked to MT-125, which represents the company's leading oncological therapy.

This grant will facilitate various aspects of the clinical trial conducted at the renowned Mayo Clinic in Jacksonville, Florida. This particular Phase 1/2 STAR-GBM clinical trial marks the inaugural examination of MT-125 in humans and will engage multiple Mayo Clinic clinical research units across the United States. The trial's Phase 1 segment will focus on assessing the safety, tolerability, and pharmacokinetics of the drug, while simultaneously gathering preliminary clinical data that will inform the subsequent Phase 2 expansion efforts.

Dr. Courtney Miller, Co-Founder and CEO of Myosin Therapeutics, expressed gratitude saying, “We are honored to receive support from the Casey DeSantis Florida Cancer Innovation Fund as we work to bring MT-125 to patients. This funding will help us continue progressing with our Phase 1/2 STAR-GBM trial and highlights the evolving strength of Florida's life sciences community, which is dedicated to advancing innovative cancer therapies.”

The Mayo Clinic campus in Florida is recognized as a leading academic medical center, playing a pivotal role in advancing new therapeutic strategies through early-stage clinical trials. By involving this site in the STAR-GBM trial, Myosin Therapeutics is expertly positioned to harness specialized neuro-oncology expertise and robust clinical trial infrastructure aimed at evaluating MT-125 in patients who have recently been diagnosed with GBM.

In addition to glioblastoma, MT-125 is being developed for various treatment-resistant cancers, including acute myeloid leukemia and pancreatic cancer. Notably, it has received Orphan Drug Designation for malignant gliomas and Fast Track Designation for glioblastoma, laying down a quicker regulatory pathway for therapies addressing significant unmet medical needs.

Moreover, Dr. Patrick Griffin, Co-founder and Chief Scientific Officer of Myosin Therapeutics, highlighted the pivotal role of the funding, stating, “This support from the Florida Department of Health will facilitate the rapid clinical development of MT-125 and strengthen Florida's growing status as a hub for biotechnology innovation. Initiatives like FCIF are crucial in enabling emerging biotechs to transform promising scientific discoveries into effective clinical programs that may ultimately benefit patients.”

As Myosin Therapeutics continues its dedication to pioneering treatments in oncology, this grant marks a significant step forward not just for the company, but for the advancing landscape of cancer treatment in Florida as a whole. With a commitment to addressing the challenges of aggressive cancers, the company strives to deliver innovative solutions that can profoundly impact patients' lives.

Conclusion

The journey toward innovative cancer therapies is often fraught with challenges, but with the support of initiatives like the Florida Cancer Innovation Fund, companies like Myosin Therapeutics can navigate the complexities associated with clinical trials and drug development. As they embark on this critical phase for MT-125, the future holds promise not just for the patients involved in the study, but for the broader medical community seeking effective solutions for some of the most daunting cancers of our time.